New Zealand Gazette – 1997 – No. 35

Page 873

✨ Medicines Consent Schedule



17 APRIL NEW ZEALAND GAZETTE

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Paroxetine hydrochloride equivalent to 20 mg paroxetine free base in 10 mL Suspension, oral SmithKline Beecham Pharmaceuticals, Manor Royal, Crawley, Sussex, England Aropax 20
Benazepril hydrochloride 5 mg, 10 mg, 20 mg Tablet, divisible Novartis Pharma Stein AG/SA Inc., Stein, Switzerland Cibacen
Benazepril hydrochloride 10 mg, 20 mg Tablet Novartis Pharma Stein AG/SA Inc., Stein, Switzerland Cibacen
Carvedilol 6.25 mg, 12.5 mg, 25 mg Tablet Boehringer Mannheim GmbH., Mannheim, Germany Dilatrend
Component 1:

Estradiol 50 mcg
Component 2:
Estradiol 50 mcg, norethisterone acetate 250 mcg
Tablet:
Norethisterone acetate 1 mg
Transdermal patch:
Oestradiol 50 mcg | Transdermal patch | Novartis Pharma Stein AG/SA Inc., Stein, Switzerland | Estracombi TTS |
| Famciclovir 125 mg, 250 mg | Tablets | SmithKline Beecham Pharmaceuticals, Magpie Wood, Manor Royal, Crawley, Sussex, England | Famvir |
| Eformoterol fumarate 12 mcg per actuation | Spray, oral, metered dose | 3M Health Care Limited, Loughborough, Leicestershire, England | Foradil |
| Tinzaparin sodium 10 000, 20 000 anti-Xa IU/mL in 2 mL | Injection, vial | Leo Pharmaceutical Products, Ballerup, Denmark and Laboratoires Leo SA., Vernouillet, France | Innohep |
| Tinzaparin sodium 10 000 anti-Xa IU/mL in 0.35 mL, 0.45 mL | Injection, pre-filled syringe | Leo Pharmaceutical Products, Ballerup, Denmark and Laboratoires Leo SA., Vernouillet, France | Innohep |
| Lamotrigine 25 mg, 50 mg, 100 mg, 200 mg | Tablet, dispersible/chewable | Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom and Glaxo Wellcome Australia Limited, Boronia, Victoria, Australia | Lamictal |
| Lamotrigine 5 mg | Tablet, dispersible/chewable | Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom | Lamictal |
| Lamotrigine 25 mg, 50 mg, 100 mg, 200 mg | Tablet | Glaxo Wellcome Operations, Temple Hill, Dartford, Kent, United Kingdom | Lamictal |
| Pancreatin with proteolytic activity equivalent to not less than 950 mcg tyrosine/min/mL | Solution, contact lens | Alcon Iberhis SA., Madrid, Spain | Opti-Plus Active Cleaner |
| Xylometazoline hydrochloride 0.1% w/v in 10 mL | Drops, nasal | Novartis Consumer Health SA., Prangins, Nyon, Switzerland | Otrivine Menthol |
| Xylometazoline hydrochloride 0.1% w/v in 10 mL | Spray, nasal, metered | Novartis Consumer Health SA., Prangins, Nyon, Switzerland | Otrivine Menthol |
| Xylometazoline hydrochloride 0.1% w/v in 10 mL | Spray, nasal | Novartis Consumer Health SA., Prangins, Nyon, Switzerland | Otrivine Menthol |
| Famotidine 10 mg | Tablet, chewable | McNeil Consumer Products Company, Round Rock, Texas, United States of America; Merck & Co Inc., West Point, Pennsylvania, United States of America and Woelm Pharma GmbH & Co., Eschwege, Germany | Pepcid AC |

Dated this 11th day of April 1997.

G. R. BOYD, Chief Advisor, Regulation and Safety, pursuant to delegation given by the Minister of Health on 20 February 1997.

go2387

Consent to the Distribution of New Medicines

Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa — PDF NZ Gazette 1997, No 35


NZLII — PDF NZ Gazette 1997, No 35




✨ LLM interpretation of page content

🏥 Consent to the Distribution of Changed Medicines (continued from previous page)

🏥 Health & Social Welfare
Medicines Act, Consent, Changed Medicines
  • G. R. Boyd, Chief Advisor, Regulation and Safety

🏥 Consent to the Distribution of New Medicines

🏥 Health & Social Welfare
11 April 1997
Medicines Act, New Medicines, Distribution
  • G. R. Boyd, Chief Advisor, Regulation and Safety